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Objective: Nerve growth factor (NGF) is a key regulator of nociceptive pain and thus appears to be an
interesting target molecule for an innovative class of analgesic medication. We set out to review the
principles of neurogenic inﬂammation and results of anti-NGF regimens in animal studies as well as
clinical trials with patients with back pain and osteoarthritis (OA).
Design: We searched using Google Scholar Search and Pubmed as well as through conference reports for
articles and abstracts related to NGF and clinical trials using anti-NGF regimens. We report on efﬁcacy
ﬁndings and adverse events (AEs) related to these agents in this review.
Results: We identiﬁed ﬁve full articles and eight abstract reports relating to anti-NGF agents studied for
use in back pain and in OA.
Conclusions: Anti-NGF agents either alone or in combination with non-steroidal anti-inﬂammatory
agents (NSAIDs) were more efﬁcacious for the treatment of pain in a number of trials of knee and hip
pain compared to NSAIDs alone. However, adverse effects that included rapidly progressive OA and joint
replacement were more common in patients treated with anti-NGF and NSAIDs than either treatment
alone. Anti-NGF treatment related neurologic symptoms including paresthesias, and potentially other
types of adverse effects were usually transient but warrant additional investigation.
 2013 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Individuals with osteoarthritis (OA) and other rheumatic dis-
eases, either inﬂammatory or degenerative, suffer from musculo-
skeletal pain. The long-term treatment of these disorders with mild
analgesics, anti-inﬂammatory agents that block the cyclooxygenase
pathways or more potent central acting narcotics is generally
inadequate. In the past decade, new pathways for nociceptive pain
induced by neurotrophins (NT) that activate peripheral sensory
nerve pathways have been studied. Inhibitors of the NT nerve
growth factor (NGF), have been developed and studied in both
preclinical models and clinical studies of painful conditions. This
review’s goal is to provide a brief update on neurogenic inﬂam-
mation, pain and in more detail the results and issues that have
arisen from the clinical studies with inhibitors of NGF inhibitors.o: N.E. Lane, Department of
5 2nd Avenue, Suite 1002,
acramento, CA 95817, USA.
e (M.F. Seidel), barton.wise@
dmc.ucdavis.edu, nelane@
Elsevier Ltd on behalf of OsteoartNeurogenic inﬂammation, NGF and pain
Degenerative disorders such as many types of OA are a conse-
quence of locally activated inﬂammation. Systemic diseases, on the
other hand, are characterized by a variety of only partially charac-
terized autoimmune stimuli, frequently with multi-organ pathol-
ogy. Both local and systemic immunopathologies show similar
patterns of activated proinﬂammatory cytokines such as tumor
necrosis factor alpha (TNF-a), several interleukins and prostaglan-
dins. These events may induce proliferation of different subsets of
cellular populations with subsequent tissue lesions, loss of function
and consequently reduced quality of life. Many of these events
might be preceded by or coincide with increasing pain sensation. In
rheumatology, painful disorders predominate in bone diseases and
arthropathies such as rheumatoid arthritis and OA. Currently, it is
unclear whether pain or inﬂammation, alone or together are the
inciting events that result in chronic joint disease. Nevertheless,
persistent peripheral nociceptor stimulation leads to a self-
perpetuating activation of neurogenic inﬂammation with typical
characteristics such as swelling, reddening and edema.
In the nervous system, several pain sensation neurotransmitters
such as substance P (SP) or calcitonin gene-related peptide (CGRP)
are able to induce peripheral inﬂammation at the site of peripheral
nociceptors after antidromal axoplasmatic transport (review1).hritis Research Society International.
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inﬂammation in experimental models2. Similarly, SP may also
initiate or cause progression of arthritis in other animal studies3.
These neurotransmitters thus show a dual mechanism of action
consisting of action potential neurotransmission to the central
nervous system (CNS) and at the same time induction or perpetu-
ation of peripheral inﬂammation.
The expression of SP and CGRP can be upregulated by NGF4. This
13 kDa polypeptide belongs to a family of NT such as brain derived
neurotrophic factor5 and several other molecules including NT-36,7,
NT-4/58,9 or NT-6. NGF was ﬁrst described as a factor for embryonal
growth anddifferentiation of neuronal crest sympathetic and sensory
neurons. In adults, it regulates neuronal regeneration from injury and
pain perception. Peripheral nociceptors express the tyrosine kinase
(Trk) A receptor that is themajor ligand for NGF. It binds toTrkAwith
high afﬁnity and to p75 with low afﬁnity. The former activates MAP
kinases, phosphatidyl inositol-3 (PI3)-kinase and Ras. p75 signaling
includes activation of Jun kinase, nuclear factor-kappaB (NF-kappaB)
and others. Since TrkA is the major receptor for NGF it may be
considered as perhaps one of the foremost receptors for pain modu-
lation. TrkAexpression is stimulated byNGF itself in basal forebrain in
rats10 suggesting that upregulation ofNGFmay result in ampliﬁcation
of pain sensation with hyperesthesia and allodynia. Conversely,
proinﬂammatory neurotransmitters induce the overexpression of
NGF which can result in a chronic self-perpetuating pain sensation
mechanism11. In addition, NGFmayalsodirectly induce inﬂammation
by activating chemotaxis in polymorphonuclear leukocytes12 and by
increasing vascular permeability13. NGF also mediates mechanical
and thermal hyperesthesia upon systemic application in animals14
and humans15.
Animal studies e pain and effect of anti-NGF regimens
Experimental animal models of pain offer the advantage to
study pathological mechanisms in more detail16. For example, pe-
ripheral joints with nociceptors, the spinal cord and the CNS are all
available for concomitant analyses of neuropeptides. Moreover,
animal strains allow a more uniform examination as compared to
genetically variant humans. Tissue analyses of experimental dis-
eases and animal behavior do not always correlate with the tar-
geted human disease. Nevertheless, animal studies provide
valuable insights into immunological events and thus may give
insight into human diseases.
Similar to NGF-upregulation in human rheumatic diseases17,
animal studies show involvement of this molecule in experi-
mental pain models. For example, NGF immunoreactivity was
shown in dorsal spinal ganglia in experimental radiculopathy18.
A similar overexpression of neuropeptides including NGF is
found in animal models with experimentally induced
arthritis19e21 and OA in dogs22. These robust NGF-related re-
actions following pain and inﬂammation suggest that anti-NGF
regimens may result in a reduction of pain perception. Indeed,
several animal studies have shown impressive anti-inﬂamma-
tory and analgesic effects23e25. In particular, pain behavior af-
ter partial ligation of the sciatic nerve was signiﬁcantly reduced
after intraperitoneal injection of anti-NGF antiserum26. Compa-
rable results were found with a TrkA antagonist (ALE-0540) after
ligation of lumbar nerve roots27. In an experimental fracture pain
model with C57BL/6J mice, an anti-NGF antibody also showed
signiﬁcant pain reduction28. MNAC13 is an anti-TrkA monoclonal
antibody that exhibited similar potent analgesic effects in
formalin-evoked pain licking responses in mice29. One experi-
mental OA model30 indicates comparable analgesic effects of an
anti-NGF regimen using the TrkA domain 5 (TrkAd5) protein, a
soluble receptor with high afﬁnity to NGF31.Anti-NGF agents for chronic low back pain (CLBP)
Several monoclonal antibodies directed against NGF have been
tested or are undergoing trials for use in the context of CLBP. This
application is predicated on the observation that treatment of CLBP
generally involves multiple modalities and is often difﬁcult to treat.
Furthermore, the medications generally utilized (non-steroidal
anti-inﬂammatory agents (NSAIDs) and opioids) may have very
signiﬁcant side effects including gastrointestinal, renal, cardiovas-
cular or CNS toxicity with potentially lethal outcomes while at the
same time there have been relatively few controlled comparative
trials that have demonstrated the efﬁcacy for long-term
applications32.
One randomized, double-blind controlled clinical trial evaluated
the use of tanezumab, a humanized anti-NGF antibody in the
context of CLBP in a population of adults with at least 3 months of
non-radiculopathic back pain requiring regular analgesic medica-
tion32. A single intravenous infusion of tanezumab was compared
with twice daily 500 mg of naproxen or placebo and study duration
was 12 weeks. The primary efﬁcacy outcome was the mean change
from baseline to week 6 in average low back pain (LBP) intensity.
Subjects in the tanezumab arm had greater decrease in average LBP
intensity than subjects in the naproxen only arm (P ¼ 0.004) or in
the placebo arm (P < 0.001) at week 6 and a higher proportion of
tanezumab-treated subjects reported “good” or “very good” LBP at
6 weeks in the Patient’s Global Assessment compared with nap-
roxen and with placebo. Treatment related adverse events (AEs)
were higher with tanezumab, the most common of which were
arthralgia, headache, myalgia, and hyperesthesia that was dose
dependent.
Another tanezumab study for chronic non-radiculopathic LBP
was performed in which subjects were randomized to receiving
tanezumab 20 mg, 10 mg or 5 mg every 8 weeks or naproxen
500 mg twice daily or placebo33. Tanezumab 20mg and 10mg both
demonstrated superiority comparedwith both naproxen (P¼ 0.006
and P ¼ 0.035 respectively) and with the placebo arm (P < 0.001
and P < 0.001 respectively) for the primary endpoint of change in
average LBP intensity from baseline to week 16. The most common
adverse event was paresthesia (ranging from 4.7 to 12.9% in the
tanezumab groups vs 1.7% in the naproxen group and 2.2% in the
placebo group), and there were no instances of osteonecrosis (ON)
or total joint replacement.
A different monoclonal antibody against NGF, fulranumab (JNJ-
42160443), has also been tested for efﬁcacy for moderate to severe
chronic LBP34. In this phase 2, multicenter double-blind trial, 389
subjects were randomized to receive fulranumab subcutaneously
monthly in a variety of doses from 1 mg to 10 mg or placebo. The
deﬁned endpoint was change in average pain score from baseline to
12 weeks, and at no dose of fulranumab did the study drug differ
from placebo (P ¼ 0.65 for 10 mg dose). The most common AEs
were diarrhea, headache, paresthesia, nasopharyngitis and upper
respiratory tract infection.
Knee and hip OA
Monoclonal antibodies targeting NGF have also been undergo-
ing testing for application in the treatment of pain in OA, particu-
larly of the hip and knee. Pain in OA ﬂuctuates over time and often
presents as episodic severe pain against a background of chronic
lower level pain, making treatment efﬁcacy difﬁcult to assess. A
number of novel anti-NGF monoclonal antibody agents have been
tested for this purpose, and a subset of trials have been reported
either in journals or in abstract form over the last few years.
In 2010, Lane et al. reported the results of a phase 2 trial of
tanezumab in 450 patients age 40e75 years with advanced OA of
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who had not had an adequate response to nonopioid pain medi-
cations35. In this study, participants were randomized to a placebo
arm or tanezumab 10, 25, 50, 100 or 200 mg per kilogram body
weight which was delivered as infusions at week 0 and week 8 and
with rescue medications of acetaminophen or tramadol allowed for
the ﬁrst 4 weeks and only acetaminophen allowed thereafter. The
primary efﬁcacy outcomes were change in walking pain and pa-
tient’s global assessment of response to therapy averaged over
weeks 1 through 16. All doses of tanezumab were superior to pla-
cebo in reduction of pain over 16 weeks (45e62% vs 22% for pla-
cebo; P < 0.001) and also in improvement by patient global
assessment (29e47% vs 19% for placebo; P < 0.001). The most
common reported AEs included headache, upper respiratory tract
infection and paresthesia that was dose dependent.
An open-label extension of the Lane study was conducted to
examine safety and effectiveness over a larger time-span36. Two
hundred and eighty one patients all received 50 mg/kg of tanezumab
at 8 week intervals up to a total of eight administrations. Patients
who in the earlier study had been receiving lower doses of the study
medication reported improvement in pain while those who had
been receiving higher dose reported some worsening of their pain
when switched to the 50 mg/kg. Mean reduction in visual analog
scale pain from baseline was reported as 12.8  1.78. The improve-
ment in pain compared with the baseline of the earlier study
appeared to persist through the 1 year of this extension study,
without reported evidence of tolerance developing. The authors
report that 7.5% of patients experienced a tanezumab-related
adverse effect, that 2.8% experienced a serious adverse event (SAE)
but that none of the SAEs were considered to be related to the study
medication, and there were no deaths. The most common adverse
effects were arthralgias (n ¼ 19, 6.8%), back pain (n ¼ 17, 6.0%) and
headaches (n ¼ 16, 5.7%), while hyperesthesia (n ¼ 1, 0.4%), hypo-
esthesia (n ¼ 9, 3.2%), peripheral neuropathy (n ¼ 1, 0.4%), pares-
thesias (n¼7, 2.5%) and sensorydisturbance (n¼1, 0.4%)wereare all
reported in 3.2% or less of the patients.
A phase 3 study has been conducted to evaluate tanezumab in
three doses (2.5, 5, or 10 mg infused at 8 week intervals) for knee
OA in comparisonwith placebo, with co-primary efﬁcacy endpoints
being change in Western Ontario and McMaster Universities OA
Index (WOMAC) pain, physical function subscale scores and Pa-
tient’s Global Assessment at week 1637. Patients were randomized
and divided equally into the four arms. For all three efﬁcacy end-
points, all three doses of tanezumabwere superior to placebo, with
what appears to be a doseeresponse pattern evident in the pro-
vided report. Mean change in WOMAC pain from baseline was
approximately 2.4, 3.1, 3.2, 3.6 for placebo and tanezumab
2.5mg, 5mg, and 10mg, respectively. AEswere reported in 55e60%
of patients who received tanezumab compared with 48% in those
receiving placebo, with more paresthesias (2.9e5.2% in tanezumab
groups vs 1.7% in placebo) and hypoesthesias (2.9e4.1% in the
tanezumab groups vs 1.2% in the placebo group) in the tanezumab
group. Four patients received joint replacements, evenly divided
across the study groups.
A randomized, double-blind study was conducted in Japan in
2008e2009 with 83 participants aged 44e73 years with knee
OA38. Patients were randomized into ﬁve groups and received a
single IV dose of tanezumab of 10 mg/kg, 25 mg/kg, 50 mg/kg,
100 mg/kg, 200 mg/kg or placebo. At 8 weeks post-infusion tane-
zumab 25 mg/kg, 100 mg/kg, 200 mg/kg showed improvement in
index knee pain during walking over placebo (18.5, 14.3,
and 27.6, respectively). AEs occurred least frequently in the
25 mg/kg group with 26.7% experiencing AEs, while 100% of pa-
tients in the 200 mg/kg group experienced AEs. Seven patients
experienced abnormal sensation, six of which were in thetanezumab groups. Three patients had severe AEs, none deemed
to be related to the study medication.
A number of abstracts have also been published reporting anti-
NGF antibody studies. In 2011 at the ACR Annual Conference,
Fidelholtz and colleagues39 reported that 610 patients with painful
knee or hip OA who received one or two doses of tanezumab 10 or
5mg or oxycodone 10e40mg every 12 h or placebowere evaluated
for WOMAC pain subscale. They found that both tanezumab doses
(P < 0.001) but not oxycodone (P ¼ 0.700) had greater improve-
ment in pain compared with placebo at week 8, and that tanezu-
mab was also superior to oxycodone in pain improvement
(P < 0.018). There was also one patient with rapidly progressive OA
(RPOA) and another with ON in the tanezumab groups (roughly
0.5%) as well as several joint replacements felt not to be related to
the study.
Also in 2011, 604 patients with moderate to severe knee or hip
OA already on diclofenac were enrolled into a randomized double-
blind placebo controlled trial. The treatment groups were tanezu-
mab at 2.5 mg, 5 mg, or 10 mg or placebo at 8 week intervals40. For
all doses of tanezumab, WOMAC pain reduction was signiﬁcantly
greater for tanezumab plus diclofenac vs placebo plus diclofenac
(1.7 for placebo vs 2.1, 2.2, and 2.3 for tanezumab 2.5 mg,
5 mg, and 10 mg respectively, taken from ﬁgure). Six tanezumab-
treated patients reported ON, but these diagnoses were not
conﬁrmed by an external adjudication committee due to insufﬁ-
cient radiographic information or because theywere determined to
be other diagnoses. Joint replacement due to possible ON, OA or
arthralgia occurred in 2.8% (n ¼ 4 subjects) of those receiving the
highest dose of tanezumab and 0.7% (n ¼ 1 subject) of those
receiving placebo.
A different study from the same group compared efﬁcacy of
tanezumab with non-steroidal anti-inﬂammatory drugs in patients
with hip or knee OA41. Patients were given naproxen 500 mg twice
daily or celecoxib 100 mg twice daily or tanezumab 5 or 10 mg
every 8 weeks or tanezumab in combination with either of the two
NSAIDs. Tanezumab with NSAID or alone was associated with
greater improvement in WOMAC pain than NSAID alone. WOMAC
pain least squares mean change over 16 weeks was 1.44 for
naproxen alone vs1.88 for tanezumab 5mg,2.02 for tanezumab
10 mg, 2.13 for tanezumab 5 mg þ naproxen, and 2.36 for
tanezumab 10 mg þ naproxen, all differences from placebo sig-
niﬁcant. WOMAC pain least squares mean change over 16 weeks
was 1.43 for celecoxib alone vs 2.02 for tanezumab 5 mg, 2.05
for tanezumab 10 mg, 2.22 for tanezumab 5 mg þ celecoxib,
and 2.41 for tanezumab 10 mg þ celecoxib, all differences from
placebo signiﬁcant. The authors observed increased risk for RPOA42
in the hip or knee in the tanezumab group compared with the
patients treated with NSAID alone.
A non-controlled but dose-blinded tanezumab study in patients
with knee or hip OA was conducted to examine longer-term efﬁ-
cacy and safety43. 2142 patients received tanezumab 2.5 mg, 5 mg,
or 10 mg every 8 weeks for up to 80 weeks. Patients who received
all three doses of tanezumab experienced WOMAC pain mean
change from baseline of approximately 4 by week 4 after the ﬁrst
infusion (from ﬁgure in abstract). Patients were reported to have
maintenance of WOMAC pain relief over the extended period. 187
patients experienced joint replacement at a greater rate in the
patients who also took NSAIDs (all cause joint replacement fre-
quency was 5.2% in those not taking NSAIDs vs 13.0% in those who
took NSAIDs).
Fulranumabwas also tested for treatment of moderate to severe
knee or hipOApain44. Patients (n¼ 466)were given dosages of 1mg
or 3 mg every 4 weeks or 3 mg, 6 mg, or 10 mg every 8 weeks or
placebo and were evaluated at the 12 weeks for average pain. Ful-
ranumab was associated with signiﬁcantly greater pain reduction
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in least square means 0.8, 95% CI: 1.49, 0.08), 6 mg every 8
weeks (0.8, 95% CI: 1.49, 0.08), and 3 mg every 4 week groups
(1.3, 95% CI: 1.97, 0.56). The most common AEs were pares-
thesia (7% overall in fulranumab groups vs 3% for placebo), headache
(6%overall vs4%placebo), hypoesthesia (4%overall vs 1% inplacebo),
nasopharyngitis (5% overall vs 1% placebo) and arthralgia (5% overall
vs 8% placebo).
Regulatory agency concerns
In 2010, the Federal Food and Drug Administration (FDA) sus-
pended clinical trials because of 492 suspected cases of ON
observed in trials conducted by Pﬁzer, Regeneron and Janssen.
These cases were observed in patients using NGF-antagonists alone
or with NSAIDs, suggesting that the signiﬁcantly greater analgesic
effect of two separate classes of drugs prompted patients to permit
increased joint load lacking the usual pain that would limit joint
stress. The observations about AEs in tanezumab studies prompted
Hochberg and colleagues to report on the process and results of
adjudication of these events45. They found 282 joints to review and
classiﬁed them into categories of ON, RPOA, normally progressive
OA, not enough information to distinguish or other joint condition.
Ultimately they identiﬁed two joints with ON, 71 with RPOA, 142
with normal progression, and 67 in the other categories. They
found a signiﬁcant doseeresponse relationship between incident
RPOA and increasing dose of tanezumab, which was greater when
tanezumab was given in combination with NSAIDs. A detailed
beneﬁterisk calculation conducted by the FDA included consider-
ations such as the imminent need for new and better tolerated
analgesic drugs that do not share side effects that are observedwith
NSAIDs or opioids. Based on these ﬁndings and the apparent low
incidence of ON, the FDA recommended reinitiating clinical studies
in March 2012.
Current plan
Clinical trials will now resume with speciﬁc consideration for
abnormal joint side effects. The study protocols that are being
considered require a careful documentation of baseline clinical and
radiographic ﬁndings of OA especially of the larger joints of the lower
extremities. Baseline X-rays of both the index joints and other large
weight bearing joints should be obtained upon entry into the clinical
study to identify potential joint pathology in the absence of clinical
involvement. Continuous clinical evaluations of the joint to include
mobility, swelling or increased pain are warranted to identify devel-
oping RPOA. Separate magnetic resonance imaging diagnostics will
also be important to consider in cases of unexpected joint pain or
swelling. Additional imaging techniques such as bone scintigraphy
mayalsobeconsidered46. Furthermore, the separate studyofdifferent
subsetsofOAsuchas inobesevsnon-obesepatients, handOAorpost-
traumatic and/ormalalignmentOAmayprovide valuable insights not
only for the underlying individual pathophysiology but also for indi-
vidual response rates. In addition to potential side effects involving
the joint anatomy, several other organ systems have to be considered
(review47). NGF is a pleiotrophic molecule that regulates a variety of
metabolic pathways and organ functions. These include the CNS, the
peripheral nervous system, wound healing, neoplastic diseases and
immunosuppression. NGF-antagonists may have an impact on all of
these organ systems although clinical trials thus far have not shown
substantial signals. One may also speculate that inhibiting pain
through anti-NGF treatment may result in increased cartilage
degradation due to overuse of joints, and this should be considered
going forward. Post marketing strategies should consider registries
for large patient cohorts similar to thosewith other biologic regimensin rheumatology. It is possible that anti-NGF therapiesmaymove into
clinical practice and ﬁnd a place in the treatment of OA pain in the
future, andcarefulpreparation forwidespreaduseof theseagentswill
be increasingly important.
Conclusion
In the light of expanding aging populations with increasing in-
cidences of OA and CLBP, novel treatment regimens are warranted
that do not share the same side effects as NSAIDs or opioids. The
selective inhibition of NGF as a key regulator of chronic pain con-
ditions shows promising results with potentially tolerable AEs.
However, current and future studies will have to appreciate the
pleiotropism of NGF with appropriate safety measures.
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